ADVERTISEMENT
News
AmnioWrap2 - BioStem Technologies
07/30/2024
BioStem Technologies initiated a 60-patient RCT to evaluate the safety and efficacy of AmnioWrap2 plus SoC vs SoC only for treatment of DFUs with primary outcome of % of wound closure over 12 weeks. Not yet recruiting; estimated study completion is Dec 2025.clinicaltrials.gov